Abstract: A flow diverting apparatus includes a stent frame body, and a stent frame extension. The stent frame body includes an inlet opening, an outlet opening, and a cavity extending from the inlet opening to the outlet opening. The stent frame body is configured to pass a flow of fluid from the inlet opening to the outlet opening through the cavity. The stent frame body includes a first portion having the inlet opening, and a second portion having the outlet opening. The second portion is tapered from one end of the second portion to a first location of the second portion, thereby forming an indented portion having a plurality of pores. The stent frame extension is configured to be disposed between at least a portion of the indented portion and a vessel wall, thereby preventing a migration of vessel wall cells onto the indented portion.

Abstract: Medication administration methods are provided for treating cardiovascular disease. A method may include administering a baseline dosage of the medication to a patient. A flow diverting apparatus may be implanted into a vessel of the patient such that blood pressure to the patient's kidneys is increased. The flow diverting apparatus is structured to partially occlude blood flow through the vessel when implanted thereby increasing upstream blood pressure. Subsequent to implanting the flow diverting apparatus, the medication dosage may be increased above, or decreased below, the baseline dosage. The dosage may be increased if the medication is a beta-blocker, an angiotensin-receptor Mocker, an angiotensin receptor enzyme inhibitor, a chymase inhibitor, a combination of an angiotensin receptor enzyme inhibitor and an angiotensin-receptor blocker, or a combination of an angiotensin receptor blocker and a neprilysin-inhibitor. The dosage may be decreased if the medication is a diuretic.

Abstract: The presently described stent-graft includes a stent frame forming a cavity and frame wires extending around the stent frame perimeter. The stent frame is formed such that the cavity cross sectional area decreases along a first length of a flow restricting section to a cavity minimum cross sectional area and increases along a second length of the flow restricting section. The first length extends from a cavity proximal cross sectional area to the cavity minimum cross sectional area and the second length extends from the cavity minimum cross sectional area to a cavity distal cross sectional area. When placed within a patient's aorta, the stent-graft may help the treatment of congestive heart failure by increasing blood flow to the kidneys. The provided stent-graft may also be adapted for placement within a patient's urethra to help the treatment of urinary incontinence.